

Guidelines for Laboratory Verification of Performance of the QIAstat-Dx[®] Respiratory SARS-CoV-2 Panel

QIAGEN GmbH, QIAGEN Strasse 1, D-40724 Hilden

Introduction

This document provides a sample protocol for the verification of the QIAstat-Dx Respiratory SARS-CoV-2 Panel (cat. no. 691223). The protocol provides positive and negative tests for the pathogens detected by the QIAstat-Dx Respiratory SARS-CoV-2 Panel.

Each laboratory is responsible for defining their verification procedure and ensuring that they meet state and federal guidelines.

Materials and methods

The procedure described below and in Table 1 generates multiple positive and negative results for each of the sample control mixes tested. The sample protocol was developed using the NATtrol[™] Respiratory Verification Panel and the NATtrol SARS-CoV-2 (E/ORF1ab) recombinant available from ZeptoMetrix[®] Corporation (Buffalo, NY; cat. no. NATRVP-QIA and 0831043, respectively).

If testing is being performed using a QIAstat-Dx Analyzer with additional Analytical Modules, the laboratory director may choose not to perform the verification protocol on each Analytical Module. If the complete verification protocol is not performed on each Analytical Module, we advise distributing test replicates evenly among the different Analytical Modules of the system.

Table 1. Overview of sample verification method

Sample protocol	
Organism controls per sample control mix	5
Number of sample control mixes	4
Replicates per sample control mix	4
QIAstat-Dx Cartridges required	16
Expected number of positive results	92
Expected number of negative results	244
Approximate days of testing	4
Number of operators	2

Performance verification materials

The materials listed in Table 2 are required to perform verification with the sample protocol.

Table 2. Materials needed for the sample verification method

Material	Catalog number	Quantity
QIAstat-Dx Respiratory SARS-CoV-2 Panel Kit (6 tests)	691223	3
QIAstat-Dx Operational Module	9002813	1
QIAstat-Dx Analytical Module(s)	9002814	1–4
NATtrol Respiratory Verification Panel	ZeptoMetrix NATRVP-QIA	1
NATtrol SARS-CoV-2 (E/ORF1ab) recombinant	ZeptoMetrix 0831043	1
Universal Transport Media (UTM)*	*	At least 5 ml
Sample tubes, 5 ml	VWR 89497-740 (or similar)	4
Transfer pipettes	VWR 13-711-43 (or similar)	24

* Refer to the *QIAstat-Dx Respiratory SARS-CoV-2 Panel Handbook* for Universal Transport Media tested with the QIAstat-Dx Respiratory SARS-CoV-2 Panel.

Sample verification method

This sample verification method describes how to prepare sample control mixes by mixing together 5 different organism controls using the ZeptoMetrix NATtrol Respiratory Verification Panel and NATtrol SARS-CoV-2 (E/ORF1ab) recombinant. Proposed mixing of organism controls is provided in Table 3. The method tests a total of 16 sample control mixes (4 sample control mixes tested in 4 replicates each). For each assay run, the method provides either 5 or 6 positive results and, correspondingly, 16 or 15 negative results for the 21 pathogens, in total, which are detected and differentiated by the QIAstat-Dx Respiratory SARS-CoV-2 Panel.

Alteration of this protocol should take into account additional lab personnel and number of instruments, based on individual laboratory needs.

Mix the organism controls to create control samples at the beginning of the sample verification method. The sample control mixes can be stored at -20°C for up to 3 days. Avoid multiple freeze–thaw cycles to prevent compromising sample integrity.

Table 3. Proposed organism control mixing and expected positive/negative results

Mix	Organism	Organism control volume [ml]	UTM volume [ml]	Final volume of mix, [ml]	Expected results	Number of expected negative results
Sample Control Mix 1	Influenza A H1N1*	0.2	1.0	2.0	positive/positive	15
	Corona HKU1	0.2			positive	
	PIV 2	0.2			positive	
	<i>C. pneumoniae</i>	0.2			positive	
	SARS-CoV-2	0.2			positive	
Sample Control Mix 2	Influenza B	0.2	1.0	2.0	positive	16
	Corona 229E	0.2			positive	
	PIV 4	0.2			positive	
	hMPV	0.2			positive	
	<i>B. pertussis</i>	0.2			positive	
Sample Control Mix 3	Influenza A H1N1/2009*	0.2	1.0	2.0	positive/positive	15
	Corona C43	0.2			positive	
	PIV 3	0.2			positive	
	Rhinovirus 1A	0.2			positive	
	RSVA	0.2			positive	
Sample Control Mix 4	Influenza A H3N2*	0.2	1.0	2.0	positive/positive	15
	Corona NL63	0.2			positive	
	PIV 1	0.2			positive	
	Adenovirus	0.2			positive	
	<i>M. pneumoniae</i>	0.2			positive	

* The Influenza A assay included in the QIAstat-Dx Respiratory SARS-CoV-2 Panel is designed to detect Influenza A as well as Influenza A subtype H1, Influenza A subtype H1N1/2009, and Influenza A subtype H3; therefore, 2 positive results (positive/positive) are expected for this pathogen.

Note that, if a seasonal Influenza A H1 strain is detected by the QIAstat-Dx Respiratory SARS-CoV-2 Panel assay, two signals are generated and displayed on the QIAstat-DX Analyzer 1.0 screen: one for Influenza A and a second one for the Influenza A subtype strain. For example, if Influenza A H1N1 is present in the sample, two positive results (positive/positive) are expected (Table 3).

Note: It is important to prepare only the number of sample control mixes that will be tested within 3 days of preparation. The number of samples prepared may be increased or decreased based on the laboratory's work schedule and number of QIAstat-Dx instruments.

Protocol

Day 1

1. Prepare Sample Control Mix 1 and Sample Control Mix 2 (refer to Table 3).
 - a. Transfer 0.2 ml of each of the organism controls in the mix to a new 5 ml tube.
 - b. Transfer the appropriate volume of universal transport medium to the 5 ml tube.
 - c. Ensure the pooled sample is effectively mixed by vortexing prior to testing.
2. Test two replicates from Sample Control Mix 1. The duplicate samples should be tested in a single day by different operators (see Table 4).
3. Repeat step 2 for Sample Control Mix 2 to be tested on the same day.
4. Store the samples at -20°C for up to 3 days for the evaluation of day-to-day variation.

Day 2

To evaluate day-to-day variation, test the remaining volume of the sample control mixes prepared on Day 1 (Sample Control Mix 1 and Sample Control Mix 2) by repeating steps 2 and 3 above.

Day 3

Prepare Sample Control Mix 3 and Sample Control Mix 4 as described in step 1. Test Sample Control Mix 3 and Sample Control Mix 4 according to steps 2 and 3.

Day 4

To evaluate day-to-day variation, test the remaining volume of the sample control mixes prepared on Day 3 (Sample Control Mix 3 and Sample Control Mix 4) by repeating steps 2 and 3 above. Table 4 details a workflow for two operators.

Table 4. Workflow for the sample verification method

	Day 1	Day 2	Day 3	Day 4
Operator 1	Sample Control Mix 1	Sample Control Mix 1	Sample Control Mix 3	Sample Control Mix 3
	Sample Control Mix 2	Sample Control Mix 2	Sample Control Mix 4	Sample Control Mix 4
Operator 2	Sample Control Mix 1	Sample Control Mix 1	Sample Control Mix 3	Sample Control Mix 3
	Sample Control Mix 2	Sample Control Mix 2	Sample Control Mix 4	Sample Control Mix 4

Revision History

Date	Changes
R1 March 2020	Initial release.
R2 March 2020	Correction of error on Table 3.

For up-to-date licensing information and product-specific disclaimers, see the respective QIAGEN kit handbook or user manual. QIAGEN kit handbooks and user manuals are available at www.qiagen.com or can be requested from QIAGEN Technical Services or your local distributor.

Trademarks: QIAGEN®, Sample to Insight®, QIAstat-Dx® (QIAGEN Group); ZepetoMetrix® (Thermo Fisher Scientific or its subsidiaries). Registered names, trademarks, etc. used in this document, even when not specifically marked as such, are not to be considered unprotected by law.

03/2020 HB-2774-501-001 © 2020 QIAGEN, all rights reserved.

